# Rusfertide

Type: Product

Source: Startup Intelligence Brief — https://getstartupbrief.com/entity/rusfertide
Canonical HTML page: https://getstartupbrief.com/entity/rusfertide

## Timeline

- **2026-02-25**: Institutional Exit — SEC filings reveal a $170 million position liquidation by a major fund.
- **2025-Q4**: 120% Rally — Stock price reaches a 12-month peak following sustained clinical momentum.
- **2025-Q1**: J&J Partnership Expansion — Johnson & Johnson expands the scope of the oral peptide collaboration.
- **2024-Q3**: Phase 2 Success — JNJ-2113 reports positive Phase 2 data in plaque psoriasis, triggering milestone payments.

## Recent coverage (1 stories)

### Protagonist Therapeutics Surges 120% as Major Fund Discloses $170M Exit
2026-02-25 21:54:31 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Protagonist Therapeutics has seen its stock price more than double following clinical breakthroughs in its oral peptide portfolio, yet a major institutional investor has liquidated a $170 million position. This tactical exit highlights the tension between clinical optimism and institutional profit-taking as the company nears critical Phase 3 milestones.
Full story: https://getstartupbrief.com/story/protagonist-therapeutics-120-percent-surge-170-million-exit

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getstartupbrief.com/guides/methodology for the full editorial methodology.